Remove Biosimilars Remove Hospitals Remove Pharmaceutical Manufacturing
article thumbnail

CPHI & PMEC India expo to be held from Nov 26-28, 2024

Express Pharma

A marketplace for innovation and growth With a comprehensive array of exhibitors, CPHI & PMEC India enables direct engagement with pharmaceutical executives, buyers, hospital administrators, and government representatives.

article thumbnail

NEW: The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

Drug Distribution Industry Expands as COVID-19 Disruption Fades and Biosimilars Boom (press release) We’re offering special discounted pricing if you order before October 21, 2022! pharmaceutical distribution industry. contains new data on hospital acquisitions and consolidation activity. Section 6.1.6.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NEW: The 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

I am pleased to announce our new 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. analyzes how marketplace dynamics of provider-administered biosimilars affect wholesalers’ gross margins. Section 4.4.

article thumbnail

D.C. Circuit Sides with Manufacturers in Latest 340B Contract Pharmacy Case

FDA Law Blog: Biosimilars

Kirschenbaum — Last week, the United States Court of Appeals for the District of Columbia ruled that Section 340B of the Public Health Service Act does not prohibit pharmaceutical manufacturers from imposing conditions on the distribution of discounted drugs to covered entities in the program. In United Therapeutics Corporation v.

article thumbnail

Exclusive Coverage: Global PHT Expo & Summit 2023

PharmaShots

Addepalli Veeranjaneyulu and Shubhadeep Debabrata Sinha introduced the session by describing the function of PV in the safety profiles of biosimilars. There was also discussion of the PV difficulties related to structure, nomenclature/ product name, manufacturing, and manufacturing variation challenges.

article thumbnail

NOW AVAILABLE: The 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

Drug Distribution Industry Gaining from Anti-Obesity Drugs and Provider-Administered Biosimilars (press release) We’re offering special discounted pricing if you order before October 20, 2023! pharmaceutical distribution industry. and Section 6.4.3. A new Section 6.2.2.